Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Tinlarebant in Adolescent Stargardt Disease (STGD1)
2021-003253-36Phase 3Active
- Sponsor
- Belite Bio, Inc
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fundus Flavimaculatus (FF) comparing Tinlarebant with Placebo (2 arms). Primary endpoint: Rate of change in aggregate area of atrophy (DDAF). Started Dec 2021; status: active.
02
Drugs
tinlarebant
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on 2021-003253-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003253-36.